You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Ineligible for Cisplatin-based Chemotherapy

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Urothelial Bladder Carcinoma Trial in Spain (Sacituzumab govitecan, Zimberelimab, Domvanalimab)

Not yet recruiting
  • Urothelial Bladder Carcinoma
  • Sacituzumab govitecan
  • +2 more
  • Santiago De Compostela, A Coruña, Spain
  • +9 more
Nov 14, 2023

Hydronephrosis, Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant, Infiltrating Bladder Urothelial Carcinoma,

Active, not recruiting
  • Hydronephrosis
  • +18 more
  • Durvalumab
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Oct 31, 2022

Bladder Cancer Trial in Fairway, Kansas City (Ascorbic Acid)

Active, not recruiting
  • Bladder Cancer
  • Ascorbic Acid
  • Fairway, Kansas
  • +2 more
Sep 21, 2022

Urothelial Carcinoma Trial in Miami, New Orleans, Rochester (MV-NIS)

Recruiting
  • Urothelial Carcinoma
  • MV-NIS
  • Miami, Florida
  • +2 more
Jun 15, 2021

Urothelial Carcinoma Trial in United States (Carboplatin, Gemcitabine, Atezolizumab)

Active, not recruiting
  • Urothelial Carcinoma
  • Indianapolis, Indiana
  • +3 more
Feb 14, 2022

Urothelial Carcinoma Trial in Iowa City (Avelumab, Docetaxel)

Active, not recruiting
  • Urothelial Carcinoma
  • Iowa City, Iowa
    University of Iowa Hospitals and Clinics
Oct 18, 2022

Head Neck Cancer, Head and Neck Tumors, Squamous Cell Carcinoma of Head and Neck Trial in Chicago (Xevinapant, Carboplatin,

Not yet recruiting
  • Head and Neck Cancer
  • +2 more
  • Chicago, Illinois
    University of Chicago Medicine Comprehensive Cancer Center
Oct 25, 2023

Muscle-invasive Bladder Cancer Trial in Berne (Durvalumab (Imfinzi), Tremelimumab)

Terminated
  • Muscle-invasive Bladder Cancer
  • Berne, Switzerland
    Departement of Medical Oncology, University Hospital Berne
Jun 16, 2020

Cholangiocarcinoma Trial in Birmingham (Novel combination of chemo and immunotherapy)

Recruiting
  • Cholangiocarcinoma
  • Novel combination of chemotherapy and immunotherapy
  • Birmingham, Alabama
    University of Alabama at Birmingham
Jul 28, 2022

Toripalimab, First-line Treatment Trial in Guangzhou (EP/EC+PD-1)

Recruiting
  • Toripalimab
  • First-line Treatment
  • Guangzhou, Guangdong, China
    Sun Yat-sen University cancer center
Mar 7, 2023

Colorectal Cancer Trial in Essen (Atezolizumab)

Recruiting
  • Colorectal Cancer
  • Essen, Germany
    Westdeutsches Tumorzentrum
Feb 14, 2022

Small Cell Lung Cancer, SCLC, Extensive Stage Small Cell Lung Cancer Trial (Durvalumab, Monalizumab, Carboplatin or Cisplatin)

Not yet recruiting
  • Small Cell Lung Cancer
  • +2 more
  • (no location specified)
Jun 5, 2023

Late Subclinical Cardiovascular Disease in Testicular Cancer

Recruiting
  • Testicular Cancer
  • +7 more
  • Lipid profile
  • +2 more
  • Indianapolis, Indiana
    Indiana University
Nov 7, 2022

FIGO Stage III Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Carcinoma Trial in Amsterdam (Cisplatin 100 mg/m2, Cisplatin 40

Not yet recruiting
  • FIGO Stage III Ovarian Cancer
  • +2 more
  • Cisplatin 100 mg/m2
  • Cisplatin 40 mg/l
  • Amsterdam, Netherlands
    Antoni van Leeuwenhoek (NKI-AVL)
Jun 3, 2022

Oropharyngeal Cancer Trial in Shanghai (Toxicities reduced treatment, Conventional treatment)

Recruiting
  • Oropharyngeal Cancer
  • Toxicities reduced treatment
  • Conventional treatment
  • Shanghai, Shanghai, China
    Eye & ENT Hospital of Fudan University
Nov 26, 2023

NSCLC Trial (Durvalumab, Tremelimumab, Pemetrexed)

Not yet recruiting
  • Carcinoma, Non-Small-Cell Lung
  • (no location specified)
Aug 17, 2023

Biliary Tract Cancer Trial in Worldwide (Durvalumab, Gemcitabine monotherapy, Gemcitabine + cisplatin)

Not yet recruiting
  • Biliary Tract Cancer
  • Durvalumab
  • +7 more
  • Orange, California
  • +36 more
Mar 6, 2023

Endothelial Function in Germ Cell Tumor Patients Treated With

Active, not recruiting
  • Germ Cell Cancer
  • Endo-PAT2000 testing
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Nov 7, 2022

Non-squamous Non-small-cell Lung Cancer Trial in Hangzhou (Tusamitamab ravtansine+Sintilimab+Carboplatin or

Not yet recruiting
  • Non-squamous Non-small-cell Lung Cancer
  • Tusamitamab ravtansine+Sintilimab+Carboplatin or Cisplatin+Pemetrexed
  • +2 more
  • Hangzhou, Zhejiang, China
    Zhejiang Cancer Hospital
May 5, 2023

Cervical Cancer Trial in Wuhan (Recombinant humanized anti-PD-1 mAb injection, Cisplatin, Bevacizumab Injection)

Not yet recruiting
  • Cervical Cancer
  • Recombinant humanized anti-PD-1 monoclonal antibody injection
  • +4 more
  • Wuhan, Hubei, China
    Tongji Hospital affiliated to Tongji Medical College of Huazhong
Nov 3, 2023

Prevention of Nausea and Vomiting Caused by Highly Emetogenic Chemo Trial (HR20013 for injection;dexamethason)

Not yet recruiting
  • Prevention of Nausea and Vomiting Caused by Highly Emetogenic Chemotherapy
  • HR20013 for injection；dexamethason
  • (no location specified)
Jul 19, 2022

Cervical Cancer Trial in Chongqing, Fuzhou (TQB2868 injection, Paclitaxel injection, Cisplatin injection)

Not yet recruiting
  • Cervical Cancer
  • TQB2868 injection
  • +4 more
  • Chongqing, Chongqing, China
  • +1 more
Aug 17, 2023

NSCLC (NSCLC) Trial (Ociperlimab, Placebo, Tislelizumab)

Not yet recruiting
  • Non-small Cell Lung Cancer (NSCLC)
  • (no location specified)
Mar 17, 2023

Advanced Urothelial Carcinoma Trial in Bern (Magrolimab, Cisplatin, Gemcitabine)

Not yet recruiting
  • Advanced Urothelial Carcinoma
  • Bern, Switzerland
    University Hospital Insel
Feb 20, 2023

Cisplatin-Ineligible Metastatic Bladder Cancer and The Role of

Not yet recruiting
  • Bladder Cancer
  • +3 more
  • Geriatric-8 Survey
  • +2 more
  • Boston, Massachusetts
  • +1 more
Nov 14, 2023